NextCure Files Definitive Proxy Statement for 2025 Annual Meeting
Ticker: NXTC · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1661059
| Field | Detail |
|---|---|
| Company | Nextcure, Inc. (NXTC) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
NextCure's proxy statement is out for the June 20th meeting - shareholders vote on directors & pay.
AI Summary
NextCure, Inc. filed its definitive proxy statement on April 25, 2025, for its annual meeting on June 20, 2025. The filing concerns the solicitation of proxies from shareholders regarding matters to be voted on at the meeting, which typically include the election of directors and executive compensation.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on corporate governance and executive compensation, impacting the company's strategic direction.
Risk Assessment
Risk Level: low — This is a standard regulatory filing (DEF 14A) for a public company's annual meeting, not indicating immediate financial or operational risk.
Key Numbers
- 23 — Public Documents (Number of documents included in the filing.)
Key Players & Entities
- NextCure, Inc. (company) — Registrant
- 20250425 (date) — Filing Date
- 20250620 (date) — Meeting Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, providing details on matters to be voted upon.
When is NextCure, Inc.'s annual meeting scheduled?
NextCure, Inc.'s annual meeting is scheduled for June 20, 2025.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 25, 2025.
What is the company's primary business as indicated by its SIC code?
NextCure, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where is NextCure, Inc. headquartered?
NextCure, Inc. is headquartered at 9000 Virginia Manor Road, Suite 200, Beltsville, MD 20705.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding NextCure, Inc. (NXTC).